

Article

Chemo-, Regio- and Stereoselective N-alkenylation of Pyrazoles/ Benzpyrazoles using Activated and Unactivated Alkynes

Vineeta Garg, Pradeep Kumar, and Akhilesh K. Verma

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.7b01746 • Publication Date (Web): 01 Sep 2017

Downloaded from <http://pubs.acs.org> on September 1, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.


Chemo-, Regio- and Stereoselective *N*-alkenylation of Pyrazoles/Benzpyrazoles using Activated and Unactivated Alkynes

Vineeta Garg, Pradeep Kumar and Akhilesh K. Verma*

Synthetic Organic Chemistry Research Laboratory, Department of Chemistry,

University of Delhi, Delhi-110007, India

Email: averma@acbr.du.ac.in



ABSTRACT: Transition-metal-free chemo-, regio- and stereoselective synthesis of (*Z*) and (*E*) styryl pyrazoles and benzpyrazoles by the addition of *N*-heterocycles onto functionalized terminal and internal alkynes using a super basic solution of KOH/DMSO has been described.




1
2
3 The stereochemical outcome of the reaction was governed by time and quantity of the base. The
4
5 reaction of pyrazoles and benzpyrazoles onto alkynes takes place chemoselectively without
6
7 affecting the free -NH_2 group of pyrazoles and -OH group of alkynes. The designed protocol
8
9 was well implemented on alkynes bearing long alkyl chain, an alicyclic ring, hydroxy, ether, and
10
11 ester functionality; offer the *N*-alkenylated products in good yields. This developed methodology
12
13 also provides easy access for the synthesis of bis-vinylated heterocycles. The presence of free -
14
15 NH_2 , -OH , -COOR and halo group in styryl pyrazoles, could be further utilized for synthetic
16
17 elaboration, which is advantageous for biological evaluation. For the first time, we have
18
19 disclosed the base-mediated conversion of (*Z*)-styryl pyrazoles to (*E*) styryl pyrazoles in
20
21 KOH/DMSO system. The *cis*-*trans* isomerization was supported by the control experiments and
22
23 deuterium labeling studies.
24
25
26
27
28

31 INTRODUCTION


32
33 Heterocycles containing potential C-N bonds have an enormous impact on organic and
34
35 medicinal chemistry.¹ In particular; alkylated pyrazoles have gained widespread interest of the
36
37 researchers over the past decade due to their vast biological significance like SR144528 (**I**) is a
38
39 potent and highly selective CB_2 receptor inverse agonist, MK-0893 (**II**) as a potent glucagon
40
41 receptor inhibitor, ruxolitinib (**III**) as a JAK 1/2 kinase inhibitor and 3-fluorophenyl urea
42
43 derivative of pyrazole (**IV**) showed a good inhibition of neutrophils chemotaxis (Figure 1).² A
44
45 broad range of pharmaceutically active ingredients like celecoxib, deracoxib, phenylbutazone,
46
47 oxyphenbutazone, feprazone, and kebuzone, possess pyrazole as a core nucleus with reduced
48
49 ulcer genic side effects.³ Pyrazoles motif act as an effective analgesic,⁴ antitubercular,⁵
50
51 anticancer,⁶ antibacterial,⁷ sodium channel blocker,⁸ anti-influenza,⁹ antioxidant and
52
53
54
55
56
57
58
59
60

Scheme 1. Synthesis of *N*-Styryl Pyrazoles/Azoles

A. Previous Work



B. Present Work



In 2008, Tsuchimoto and co-workers reported the silver and zinc-catalyzed addition of N-H of pyrazoles onto alkynes using high catalyst loading (Scheme 1, ii).²⁷ Recently, Bhattacharjee²⁸ and fellow workers use ruthenium complexes $[\text{Ru}(\text{dpppe})(\text{PPh}_3)(\text{CH}_3\text{CN})_2\text{Cl}][\text{BPh}_4]$ and $[\text{Ru}(\text{dppp})_2(\text{PPh}_3)(\text{CH}_3\text{CN})\text{Cl}][\text{BPh}_4]$ for the generation of *E* and *Z* isomer respectively (Scheme 1, iii). Metal-free hydroamination has been explored by Trofimov,²⁹ and our group³⁰ using super

1
2
3 basic system (KOH/DMSO). However, the synthesis of *N*-alkenylated pyrazoles in regio-,
4
5 chemo- and stereo-selective fashion with aliphatic as well as aromatic alkynes under metal-free
6
7 condition is challenging.
8
9

10 Inspired by our previous reports on hydroamination,³⁰ herein, we have described a facile
11
12 and versatile protocol for the construction of functionalized (*E*) and (*Z*) vinylated pyrazoles and
13
14 benzpyrazoles with activated and unactivated alkynes in KOH/DMSO system (Scheme 1, iv).
15
16

17 RESULTS AND DISCUSSION

















19 To identify the optimal reaction conditions, we initiated the reaction of pyrazole (**1a**)
20
21 with phenyl acetylene (**2a**) using our reported conditions^{30d} that is 0.2 equiv of KOH in
22
23 DMSO at 120 °C for 30 min, afforded the (*Z*)-1-styryl-1*H*-pyrazole (**3a**) in 58% yield (Table
24
25 1, entry 1). Increasing the amount of base from 0.2 to 0.5 equiv, provided the (*Z*)-styryl
26
27 product **3a** in 74% yield (entry 2), however; further increasing the amount of base, decreases
28
29 the yield of (*Z*)-styryl product (entry 3). Thus, 0.5 equiv of the base in 30 min was found to be
30
31 efficient for obtaining (*Z*)-styryl product. When the reaction was allowed to stir for 24 h using
32
33 0.5 equiv of a base mixture of stereoisomers (*Z*:*E*::70:30) was obtained in 70% yield (entry 4).
34
35 Increase in the amount of base from 0.5 equiv to 1.0 equiv led to the formation of *E* isomer in
36
37 the ratio (*Z*:*E*::40:60) (entry 5). Further, to obtain the *E*-selective product we increase the
38
39 amount of base from 1.0 to 1.5 and then to 2.0 equiv, interestingly we obtained (*E*)-styryl
40
41 product **4a** (*Z*:*E*::0:100) exclusively in 68% yield (entries 6 and 7). The lower yield was
42
43 obtained with other bases such as NaOH, CsOH.H₂O, KO^tBu, and K₃PO₄ in DMSO (entries 8–
44
45 11). An organic base such as Et₃N was found to be ineffective for the reaction (entry 12). The
46
47 above results confirmed that the reaction time, as well as the amount of base, was important to
48
49 control the stereoselectivity of the reaction.
50
51
52
53
54
55
56
57
58
59
60


alkynes **2b–g** were used, the desired (*Z*)-styryl products **3b–g** were obtained in 67–72% yields (entries 2–7). The reaction of hetero alkyne **2h** was also successful in providing the desired product **3h** in good yield (entry 8). Interestingly, 2-ethynylphenylmethanol **2i** bearing primary alcoholic group afforded the product **3i** in 65 % yield, without affecting the free –OH group (entry 9).

The designed methodology was well tolerated for substituted pyrazole having –CH₃ and –NH₂ functionality, and afforded the desired products **3j–k** chemoselectively in good yield without affecting free –NH₂ group (entries 10-11). Significantly, electron-withdrawing and halogen substituted pyrazoles having –CF₃, –NO₂ and –Br group afforded the hydroaminated products **3l–n** in 68-70% yields (entries 12-14). The sterically hindered pyrazoles were also reacted smoothly with substituted terminal alkynes **2m**, **2b** and provided the corresponding hydroaminated products **3o** and **3p** in good yields (entries 15-16).

Table 2. Synthesis of *Z*-Styryl Pyrazoles^a


entry	pyrazoles	alkyne 2	(<i>Z</i>) product 3	yield (%) ^b
1				74
2	1a			72

1						
2						
3	1a		2c		3c	70
4	1a		2d		3d	71
5	1a		2e		3e	68
6	1a		2f		3f	69
7	1a		2g		3g	67
8	1a		2h		3h	68
9	1a		2i		3i	65
10 ^c	1b		2a		3j	73
11 ^c	1c		2j		3k	65



^aThe reactions were performed using pyrazoles **1** (0.5 mmol), 1.0 mmol of alkynes **2**, 0.5 equiv of KOH in 2.0 mL of DMSO at 120 °C for 0.5 h. ^b Isolated yields. ^c Reaction run for 4 h.

After obtaining the selective *Z*-styryl product, we extended the scope of the developed chemistry for the stereoselective synthesis of (*E*)-styryl pyrazoles **4a–g** in good yields (Scheme 2). The reaction of pyrazole **1a** with substituted alkynes **2a–b** and **2n–p** in the presence of 2.0 equiv KOH in DMSO at 120 °C for 24 h gave the *E*-styryl products **4a–e** in 65–70% yield. Electron withdrawing aryl alkynes such as 1-ethynyl-4-(trifluoromethyl)benzene **2q** and 1-ethynyl-4-nitrobenzene **2r** provided the desired *E*-styryl product **4h–i** in moderate yield with excellent selectivity.

Scheme 2. Synthesis of *E*-Styryl Pyrazoles^a


^aThe reactions were performed using pyrazoles **1** (0.5 mmol), 1 mmol of alkynes **2**, 2.0 equiv of KOH in 2.0 mL of DMSO at 120 °C for 24 h. ^bReaction completed in 6 h. ^cReaction run for 0.5 h with 50% recovery of starting substrate.

In past decades hydroamination reactions on aliphatic alkynes have been reported using expensive metal catalyst.²⁷⁻²⁸ Therefore, we examined the developed strategy for aliphatic alkynes **2aa-ak** bearing long chain, an alicyclic ring, hydroxyl, ether, and ester group were utilized for the synthesis of *N*-alkenylated pyrazoles **5a-m** in 40-69% yields (Table 3). The reaction with aliphatic alkyne **2aa** and **2ab** provided the (*Z*)-vinylated products **5a-b** in good yields (entries 1-2). Interestingly, when a primary alcoholic group containing alkynes **2ac-ad** were employed under standard reaction conditions, the reaction gave the hydroaminated products **5c-d** in fair yields instead of hydroxylation on primary alcohol (entries 3-4). However, the reaction with 1-ethynylcyclopentanol **2ae** and 1-ethynylcyclohexanol **2af** afforded the corresponding products **5e** and **5f** in 55% and 60% yields, respectively (entries 5 and 6). Similarly, methyl and phenyl propargyl ether **2ag-ah** were also found compatible to provide the *Z*-alkenylated products **5g** and **5h** in good yields (entries 7-8). Substituted pyrazoles having
















10

electron-withdrawing group were also successful in providing the hydroaminated products **5i–j** in 59–69% yield (entries 9–10). 4-Bromo-1*H*-pyrazole (**1f**) gave the fruitful yield of desired products **5k–l** with 1-hexyne **2ai** and 1-pentynol **2aj** (entries 12–13). Surprisingly, the reaction of products **5k–l** with 1-hexyne **2ai** and 1-pentynol **2aj** (entries 12–13). Surprisingly, the reaction of ethyl propiolate **2ak** with pyrazole **1a** provided the hydroaminated product **5m** in 66% yield with absolute *E*-stereoselectivity (entry 14). The formation of *N*-alkenylated products reveals the efficacy, functional group tolerance and chemoselective behavior of designed protocol.


Table 3. Scope of Aliphatic Alkynes^a



entry	pyrazoles	alkyne 2a		product 5	yield (%) ^b
1	1a		2aa		5a 62
2	1a		2ab		5b 60
3	1a		2ac		5c 68
4	1a		2ad		5d 58

5	1a		2ae		5e	55
6	1a		2af		5f	60
7	1a		2ag		5g	68
8	1a		2ah		5h	60
9	1d		2ac		5i	69
10	1d		2ab		5j	59
11	1f		2ai		5k	40
12	1f		2aj		5l	60
13 ^c	1a		2ak		5m	66

^aThe reactions were performed using **1a-c** (0.5 mmol), alkyne **2** (1.0 mmol), and 1.0 equiv of KOH in 2.0 mL of DMSO at 120 °C for 5 h. ^b Isolated yields. ^c Reaction completed in 0.5 h.


Scheme 3. Scope of Internal Alkynes^a

^aThe reactions were performed using pyrazoles **1** (0.5 mmol), alkynes **2** (0.5 mmol), 1.5 equiv of KOH in 2.0 mL of DMSO at 120 °C for 24 h. ^bReaction completed in 3 h.

We next examined the scope and efficacy of the reaction by employing a wide range of substituted symmetrical and unsymmetrical internal alkynes **6a-h** with pyrazoles **1** to synthesize

1
2
3 corresponding hydroaminated product **7** in regioselective manner (Scheme 3). Nucleophilic
4 addition of pyrazole **1a** provided the desired product **7a** with diphenylacetylene **6a** in good
5 yields. However, 1,2-di-*p*-tolylethyne **6b** and 1-methyl-3-(*p*-tolylethynyl)benzene **6c** afforded the
6 hydroaminated products **7b-c** in 65-68% yields. It was observed that alkyne **6d** reacted more
7 promptly with **1a** and gave the desired product **7d** in 71% yield. Electron-withdrawing group
8 containing alkyne **6e** yielded the addition product **7e** in 70% yield whereas electron-rich alkyne
9 **6f** afforded the desired product **7f** in 62% yield. Aryl alkyl internal alkynes, prop-1-yn-1-
10 ylbenzene **6g** and 3-phenylprop-2-yn-1-ol **6h**, gave the *N*-alkenylated products **7g** and **7h** in good
11 yields. Similarly, commendable results were obtained when the reaction of 3-methyl pyrazole **1b**
12 with alkyne **6g** was performed. The reaction of trifluoromethane substituted pyrazoles **1d** with
13 alkyne **6a** leads to the formation of desired product **7j** in 65% yield whereas bromo substituted
14 pyrazoles **1f** gave the product **7k** in 63% yield. The regioselectivity of the reaction was
15 recognized by chemical shifts, coupling constants (J_{H-H}), and NOESY studies (see SI).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33


34 After synthesizing the library of *N*-styryl pyrazoles from differently substituted aromatic
35 and aliphatic alkynes with pyrazoles in good yields, further efforts were carried out to explore
36 the benzpyrazoles in the reaction. The benzpyrazoles **1k-l**, having -Br functionality reacted with
37 terminal and internal alkynes and gave the (*Z*)-5/6-bromo-1-styryl-1*H*-indazoles **8a-g** in good
38 yield (Scheme 4). The addition of 5-bromobenzpyrazoles **1k** on alkyne **2a** provided the product
39 **8a** in 65% yield. However, alkyne **2b** and **2n** afforded the corresponding *Z*-addition products **8b-**
40 **c** in 63-67% yield. Alkyne **2h** containing thienyl ring gave the desired product **8d** in 60% yield.
41 Similarly, the reaction of 6 bromo-1*H*-indazoles **1l** afforded the hydroaminated products **8e** and
42 **8f** with alkynes **2a** and **2c** in 62% and 60% yields respectively. Reactions of internal alkynes **6a**
43 with **1k** provided the styryl products **8g** in good yield using 2.0 equiv of KOH at 120 °C for 36 h.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 4. Synthesis of (*Z*)-5/6-bromo-1-styryl-1*H*-indazoles^a

^aThe reactions were performed using benzopyrazoles **1** (0.5 mmol), alkynes **2** (1.0 mmol), 1 equiv of KOH in 2.0 mL of DMSO at 120 °C for 8 h. ^bbenzopyrazole **1l** (0.5 mmol), alkynes **2** (0.5 mmol), 2.0 equiv of KOH for 36 h.

Encouraged by above results, we explore 1, 3 and 1, 4 diethynyl benzene **2r** and **2s** for the synthesis of bis-vinylated *N*-heterocycles compound **9a-e** (Scheme 5, a). The reaction was carried out by using 1.0 equiv of KOH at 120 °C with 4-iodo-1*H*-pyrazole **1m** for 0.5 h, provided the bis hydroaminated product **9a** in 58% yield. The reaction was also compatible with benzopyrazoles to synthesize the 1,4-bis((*Z*)-2-(6-bromo-1*H*-indazol-1-yl)vinyl)benzene **9b** in 2 h (Scheme 5, b). The reaction of triazole **1n** with alkynes **2r** along with pyrazole **1a** furnish the 1-(((*Z*)-3-(((*Z*)-2-(1*H*-pyrazol-1-yl)vinyl)styryl)-1*H*-1,2,4-triazole **9c** in 59% yields (Scheme 5, c). Similarly, indole **1o** and pyrazole **1a** with alkyne **2s** gave the bis-hydroaminated product **9d** in good yield. Further, we elaborate the scope of reaction with 1,4-bis(4-methoxyphenyl)buta-1,3-diyne **2t** and **1a**; we obtained the hydroaminated product **9e** in 48% yield selectively (Scheme 5, e).

Scheme 5. Hydroamination on Dialkynes







(a) The reactions were performed using pyrazole **1m** (0.5 mmol), 0.25 mmol of the alkyne **2r**, 1.0 equiv of KOH in 2.0 mL of DMSO at 120 °C for 0.5 h. (b) Benzpyrazole **1l** (0.5 mmol), 0.25 mmol of the alkyne **2s**, 1.0 equiv of KOH in 2.0 mL of DMSO at 120 °C for 2 h. (c) Pyrazole **1a** (0.5 mmol) along with triazole **1n** (0.5 mmol), 0.25 mmol of the alkyne **2r**, 1.0 equiv of KOH in 2.0 mL of DMSO at 120 °C for 2 h. (d) Pyrazole **1a** (0.5 mmol) along with indole **1o** (0.5 mmol), 0.25 mmol of the alkyne **2s**, 1.0 equiv of KOH in 2.0 mL of DMSO at 120 °C for 2 h. (e) Pyrazole **1a** (0.5 mmol), 0.25 mmol of the alkyne **2t**, 0.5 equiv of KOH in 2.0 mL of DMSO at 120 °C for 0.5 h.

1
2
3 Inspired by our previously reported mechanistic studies of hydrophenoxylation^{31a} and
4 hydrothiolation^{31b} using KOH/DMSO system. Further, we explore the cis to trans isomerization
5 in hydroamination. The reaction in deuterated DMSO-*d*₆ furnished deuterium labeled at styryl
6 position in compounds **10a-d** indicates the source of the styryl proton was solvent (Scheme 6A).
7
8 Similarly, no reaction occurs when the reaction is carried out with isolated (*Z*)-isomer **3a** using
9 KOH/Toluene system for 36 h (Scheme 6B). These experiments confirmed that the source of
10 styryl proton is DMSO, and experiment 6B suggested the exchange of proton was facilitating in
11 KOH/DMSO system.
12
13
14
15
16
17
18
19
20
21

22 Further studies were focused on to understand the involvement of our catalyst system in
23 cis to trans isomerization by performing the reaction in DMSO without KOH, the starting
24 material remains unchanged (scheme 6C). This control experiment confirmed the presence of
25 KOH/DMSO catalytic system is crucial for the reaction, probably the KOH functioning as an
26 initiator in the scrambling of DMSO. The compound **3a** was treated with KOH/DMSO system;
27 the *E*-product **4a** was obtained in 68% in 24 h (Scheme 6D, i). Next reaction was performed in
28 KOH/DMSO-*d*₆, and the product **10e** was achieved with deuterium-labeled at styryl position
29 (scheme 6D, ii). Further running the reaction for more time from 20 h to 24, 30 and 40 h in
30 KOH/DMSO-*d*₆ provided the deuterated compounds **10f-h** in different deuterium percentage up
31 to 100% (scheme 6C, iii-v). The Comparative ¹H NMR spectrum studies of cis-trans conversion
32 in DMSO/DMSO-*d*₆ with various reaction intervals are shown in Figure 2.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 6. Deuterium Labeling and Control Experiments: Cis to Trans Isomerization

**B. Reaction in Toluene****C. Reaction in DMSO****D. Cis-trans isomerization**






Figure 2. ^1H NMR Spectrum studies of cis to trans conversion and deuterium exchange in DMSO/DMSO-d₆. (i) Reaction in DMSO after 0.5 h. (ii) Reaction in DMSO after 24 h. (iii) Reaction in DMSO-d₆ after 6 h. (iv) Reaction in DMSO-d₆ after 24 h. (v) Reaction in DMSO-d₆ after 30 h. (vi) Reaction in DMSO-d₆ after 40 h.

Scheme 7. Plausible Mechanism



In the illumination of preliminary experiments, we proposed the possible mechanistic pathway for the synthesis of cis hydroaminated product **3a-d₂** and their conversion to trans isomer **10** via intermediate **V**. The formation of cis isomer was initiated by the attack of pyrazole anion **1'** on alkyne **2-d₁** to form alkenyl anion **I** (Scheme 7). Subsequently, kinetically stable Z-enamines **3a-d₂** changed into iminium ion **II** by the migration of pyrazole lone pair towards adjacent carbon. The intermediate **II** converted into intermediate **III** which after deuterium exchange generates trans isomer **V**. Further deuteration of intermediate **V** generated the compound **10** via intermediate **VI** and **VII**. The above experiments concluded that initially, the kinetic control leads to the formation of Z isomer but later on, the thermodynamic control converts the Z- to E-isomer.

Scheme 8. Synthetic Transformation



Having explored the variety of simple and substituted pyrazoles and benzpyrazoles with aromatic and aliphatic alkynes, further we carried out synthetic transformation of our designed *N*-vinylated pyrazoles (**3a** and **4a**) through reduction of styryl bond using 10 mol % of Pd/C in EtOAc:MeOH (4:1). Next, we diversified bromo handle compound **8c** by palladium-catalyzed Sonogashira coupling reaction (Scheme 8).

CONCLUSIONS

In summary, we have envisaged a versatile and efficient regio-, chemo- and stereoselective synthetic approach to produce a broad range of functionalized (*E*) and (*Z*) styryl pyrazole and benzpyrazole derivatives which can be used as precursors for the synthesis of biologically active molecules. We also disclosed the implementation of aliphatic alkynes in hydroamination using metal and ligand-free protocol. This method provides the simplest way for the synthesis of symmetrical and unsymmetrical bis-vinylated heterocyclic compounds. Deuterium labeling and control experiments demonstrate the role of KOH/DMSO catalytic system in the *cis*-*trans* isomerization, which was further supported by comparative ¹H NMR spectrum studies in DMSO/DMSO-*d*₆.

EXPERIMENTAL SECTION

General Information and Method. All the reactions were performed in an oven-dried Schlenk flask under an argon atmosphere. Column chromatography was performed using silica gel (mesh 100-200). TLC analysis was performed on commercially prepared 60 F₂₅₄ silica gel plates. Visualization of spots on TLC plate was accomplished with UV light (254 nm) and staining over I₂ chamber. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded in CDCl₃ and (CD₃)₂SO. Chemical shifts for carbons are reported in ppm from tetramethylsilane and are referenced to the carbon resonance of the solvent. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, br s = broad singlet), coupling constants in Hertz, and integration. High-resolution mass spectra were recorded with q-TOF electrospray mass spectrometer. All purchased chemicals were used as received. All melting points are uncorrected.

General procedure for the synthesis of (Z)-styryl pyrazoles (3a-p): In an oven dried pressure tube, to a solution of pyrazoles **1a-h** (0.5 mmol) in DMSO, finely crushed KOH (0.5 equiv) and alkynes **2a-m** (1.0 mmol) were added under inert atmosphere. The resulting reaction mixture was heated at 120 °C for 30 min. Progression of the reaction was monitored by TLC, while noticing complete consumption of alkynes, reaction was brought to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel mesh size 100-200 (hexane).

(Z)-1-Styryl-1H-pyrazole (3a). The product was obtained as yellow oil (62.9 mg, 74% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, 1H), 7.30-7.27 (m, 4H), 7.20-7.18 (m, 2H), 7.00 (d, *J* =

1
2
3 9.7 Hz, 1H), 6.25 (d, $J = 9.7$ Hz, 1H), 6.19–6.18 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.2,
4
5 134.3, 129.4, 128.61, 128.56, 127.8, 126.9, 118.9, 106.6; HRMS (ESI-TOF) m/z : (M+H) $^+$ Calcd
6
7 for $\text{C}_{11}\text{H}_{11}\text{N}_2$ 171.0922; found 171.0915.
8
9

10
11 (*Z*)-1-(4-Methylstyryl)-1H-pyrazole (**3b**). The product was obtained as a yellow semi-solid
12
13 (66.2 mg, 72% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.49 (s, 1H), 7.245–7.240 (m, 1H), 7.02–
14
15 6.96 (m, 4H), 6.86 (d, $J = 9.1$ Hz, 1H), 6.14–6.09 (m, 2H), 2.23 (s, 3H); ^{13}C NMR (100 MHz,
16
17 CDCl_3) δ 140.0, 137.6, 131.2, 129.4, 129.1, 128.4, 126.3, 119.3, 106.4, 21.1; HRMS (ESI-TOF)
18
19 m/z : (M+H) $^+$ Calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2$ 185.1079; found 185.1080.
20
21
22
23

24 (*Z*)-1-(4-Ethylstyryl)-1H-pyrazole (**3c**). The product was obtained as a pale yellow oil (69.3
25
26 mg, 70% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.484–7.482 (m, 1H), 7.246–7.240 (m, 1H),
27
28 7.03–6.98 (m, 4H), 6.85 (d, $J = 9.7$ Hz, 1H), 6.11 (d, $J = 9.7$ Hz, 1H), 6.08 (t, $J = 1.8$ Hz, 1H),
29
30 2.52 (q, $J = 7.3$ Hz, 2H), 1.12 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.0, 140.0,
31
32 131.4, 129.4, 128.6, 128.0, 126.3, 119.4, 106.4, 28.5, 15.3; HRMS (ESI-TOF) m/z : (M+H) $^+$
33
34 Calcd for $\text{C}_{13}\text{H}_{15}\text{N}_2$ 199.1235; found 199.1226.
35
36
37
38

39 (*Z*)-1-(4-Butylstyryl)-1H-pyrazole (**3d**). The product was obtained as a pale yellow oil (80.2
40
41 mg, 71% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.59 (s, 1H), 7.356–7.351 (m, 1H), 7.12–7.07
42
43 (m, 4H), 6.96 (d, $J = 9.1$ Hz, 1H), 6.25–6.20 (m, 2H), 2.58 (t, $J = 7.6$ Hz, 2H), 1.58–1.55 (m,
44
45 2H), 1.38–1.34 (m, 2H), 0.94–0.90 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 142.8, 140.2, 131.5,
46
47 129.50, 128.62, 128.55, 126.4, 119.5, 106.5, 35.4, 33.4, 23.3, 13.9; HRMS (ESI-TOF) m/z :
48
49 (M+H) $^+$ Calcd for $\text{C}_{15}\text{H}_{19}\text{N}_2$ 227.1548; found 227.1557.
50
51
52
53

54 (*Z*)-1-(4-Methoxystyryl)-1H-pyrazole (**3e**). The product was obtained as a brown oil (68.0
55
56 mg, 68% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.52 (s, 1H), 7.287–7.281 (m, 1H), 7.02 (d, $J =$
57
58 23
59
60

1
2
3 8.2 Hz, 2H), 6.84 (d, $J = 10.8$ Hz, 1H), 6.74 (d, $J = 9.6$ Hz, 2H), 6.15–6.13 (m, 2H), 3.72 (s, 3H);
4
5 ^{13}C NMR (100 MHz, CDCl_3) δ 159.2, 140.1, 130.0, 129.5, 126.5, 125.7, 119.8, 113.9, 106.4,
6
7
8 55.2. HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}$ 201.1028; found 201.1017.
9

10
11 *(Z)*-1-(4-Phenoxystyryl)-1H-pyrazole (**3f**). The product was obtained as colorless oil (90.3
12 mg, 69% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.594–7.591 (m, 1H), 7.378–7.372 (m, 1H), 7.33
13
14 (t, $J = 8.3$ Hz, 2H), 7.14–7.10 (m, 3H), 7.02 (d, $J = 7.9$ Hz, 2H), 6.94 (d, $J = 9.7$ Hz, 1H), 6.91–
15
16 6.89 (m, 2H), 6.22–6.19 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.1, 156.4, 140.2, 130.2,
17
18 129.7, 129.4, 128.8, 126.2, 123.6, 119.2, 118.9, 118.3, 106.6; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$
19
20 Calcd for $\text{C}_{17}\text{H}_{15}\text{N}_2\text{O}$ 263.1184; found 263.1178.
21
22
23
24
25

26
27 *(Z)*-1-(2-(6-Methoxynaphthalen-2-yl)vinyl)-1H-pyrazole (**3g**). The product was obtained
28 as a pale yellow solid (83.7 mg, 67% yield), mp 91–94 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.66–
29 7.60 (m, 1H), 7.58 (d, $J = 4.8$ Hz, 1H), 7.55 (s, 2H) 7.277–7.271 (m, 1H), 7.12–7.10 (m, 1H),
30 7.06 (dd, $J = 9.1$ and 2.4 Hz, 1H), 7.029–7.024 (m, 1H), 6.98 (d, $J = 9.7$ Hz, 1H), 6.32 (d, $J = 9.7$
31 Hz, 1H), 6.12–6.11 (m, 1H), 3.84 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.1, 140.2, 134.0,
32
33 129.7, 129.5, 129.4, 128.8, 127.9, 127.0, 126.8, 126.6, 119.7, 119.2, 106.6, 105.7, 55.3; HRMS
34
35 (ESI-TOF) m/z : $(\text{M}+\text{Na})^+$ Calcd for $\text{C}_{16}\text{H}_{14}\text{N}_2\text{ONa}$ 273.1004; found 273.1006.
36
37
38
39
40
41
42
43

44 *(Z)*-1-(2-(Thiophen-3-yl)vinyl)-1H-pyrazole (**3h**). The product was obtained as a yellow
45 semi-solid (59.8 mg, 68% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.57–7.56 (m, 1H), 7.37–7.36
46 (m, 1H), 7.18–7.14 (m, 2H), 6.83 (d, $J = 9.1$ Hz, 1H), 6.73 (dd, $J = 4.8$ and 1.2 Hz, 1H), 6.22–
47 6.21 (m, 1H), 6.19 (d, $J = 9.1$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0, 134.0, 129.4,
48
49 127.8, 127.3, 126.0, 123.7, 119.1, 107.2; HRMS (ESI-TOF) m/z : $(\text{M}+\text{Na})^+$ Calcd for $\text{C}_9\text{H}_8\text{N}_2\text{SNa}$
50
51 199.0306; found 199.0306.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*Z*)-2-(2-(1*H*-Pyrazol-1-yl)vinyl)phenyl)methanol (**3i**). The product was obtained as yellow solid (65.0 mg, 65% yield), mp 91–94 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.50–7.49 (m, 2H), 7.34 (t, *J* = 6.8 Hz, 1H), 7.27–7.23 (m, 1H), 7.14–7.13 (m, 1H), 7.13–7.11 (m, 1H), 7.07 (d, *J* = 2.2 Hz, 1H), 6.31 (d, *J* = 9.9 Hz, 1H), 6.12 (t, *J* = 2.2 Hz, 1H), 4.61 (s, 2H), 2.52 (br s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 140.2, 138.9, 133.4, 129.2, 128.8, 128.22, 128.17, 127.9, 115.1, 107.0, 63.1; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₂H₁₃N₂O 201.1028; found 201.1024.

(*Z*)-3-Methyl-1-styryl-1*H*-pyrazole (**3j**). The product was obtained as a yellow semi-solid (67.1 mg, 73% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.59 (s, 1H), 7.24–7.22 (m, 3H), 6.95–6.94 (m, 2H), 6.81 (d, *J* = 9.1 Hz, 1H), 6.55 (d, *J* = 8.3 Hz, 1H), 6.08 (s, 1H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 149.6, 134.7, 130.2, 128.9, 128.7, 128.6, 127.6, 117.4, 106.6, 13.5; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₂H₁₃N₂ 185.1079; found 185.1080.

(*Z*)-1-(3-Aminostyryl)-1*H*-pyrazol-4-amine (**3k**). The product was obtained as a yellow semi-solid (65.0 mg, 65% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 2.2 Hz, 1H), 7.09–7.05 (m, 1H), 6.69 (d, *J* = 9.9 Hz, 1H), 6.64 (d, *J* = 7.6 Hz, 1H), 6.56–6.54 (m, 2H), 5.93 (d, *J* = 9.9 Hz, 1H), 5.55 (d, *J* = 3.0 Hz, 1H), 3.64 (br s, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 154.8, 146.5, 135.9, 131.1, 129.4, 126.4, 118.9, 115.6, 114.9, 114.2, 95.3; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₁H₁₃N₄ 201.1140; found 201.1135.

(*Z*)-1-(3-Methoxystyryl)-3-(trifluoromethyl)-1*H*-pyrazole (**3l**). The product was obtained as a yellow oil (91.1 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.26 (s, 1H), 7.19–7.15 (m, 1H), 6.91 (d, *J* = 9.1 Hz, 1H), 6.78 (dd, *J* = 8.5 and 2.4 Hz, 1H), 6.69 (d, *J* = 7.9 Hz, 1H), 6.60 (s, 1H), 6.38–6.34 (m, 2H), 3.65 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 134.6, 131.3,

1
2
3 130.0, 126.4, 122.4, 122.3, 121.0, 114.5, 113.4, 105.0, 55.1; HRMS (ESI-TOF) m/z : (M+H)⁺
4
5
6 Calcd for C₁₃H₁₂F₃N₂O 269.0902; found 269.0909.
7

8
9 (*Z*)-1-(3-Methylstyryl)-4-nitro-1H-pyrazole (**3m**). The product was obtained as a yellow
10 semi-solid (80.1 mg, 70% yield), ¹H NMR (400 MHz, CDCl₃) δ 8.07 (s, 1H), 7.91 (s, 1H), 7.16
11 (t, *J* = 8.3 Hz, 1H), 7.08–7.07 (m, 1H), 6.91 (s, 1H), 6.87–6.82 (m, 2H), 6.45 (d, *J* = 10.6 Hz,
12 1H), 2.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 139.0, 136.1, 136.0, 132.4, 129.8, 129.0,
13 128.9, 128.6, 125.5, 125.1, 124.5, 21.4; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd for C₁₂H₁₂N₃O₂
14 230.0930; found 230.0917.
15
16
17
18
19
20
21
22

23
24 (*Z*)-4-Bromo-1-styryl-1H-pyrazole (**3n**). The product was obtained as a yellow liquid (83.9
25 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.46 (s, 1H), 7.29–7.21 (m, 4H) 7.13–7.11 (m,
26 2H), 6.84 (d, *J* = 9.6 Hz, 1H), 6.22 (d, *J* = 9.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 140.8,
27 133.7, 129.4, 128.8, 128.5, 128.2, 126.5, 119.8, 94.6; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd for
28 C₁₁H₁₀BrN₂ 249.0027; found 249.0051.
29
30
31
32
33
34
35

36
37 (*Z*)-5-Methyl-1-(4-(trifluoromethoxy)styryl)-1H-pyrazol-3-amine (**3o**). The product was
38 obtained as a yellow semi-solid (101.8 mg, 72% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.22 (d, *J*
39 = 9.5 Hz, 2H), 7.07 (d, *J* = 8.3 Hz, 2H), 6.60 (d, *J* = 9.1 Hz, 1H), 6.18 (d, *J* = 9.1 Hz, 1H), 5.48
40 (s, 1H), 3.70 (br s, 2H), 1.98 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.7, 148.3, 140.8, 133.2,
41 130.5, 124.1, 121.7, 121.3, 120.4, 95.0, 11.3; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd for
42 C₁₃H₁₃F₃N₃O 284.1011; found 284.1006.
43
44
45
46
47
48
49
50

51
52 (*Z*)-3,5-Dimethyl-1-(4-methylstyryl)-1H-pyrazole (**3p**). The product was obtained as a
53 yellow semi-solid (68.9 mg, 65% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.00 (d, *J* = 8.3 Hz, 2H),
54 6.84 (d, *J* = 7.6 Hz, 2H), 6.66 (d, *J* = 9.1 Hz, 1H), 6.40 (d, *J* = 9.1 Hz, 1H), 5.83 (s, 1H), 2.26 (s,
55
56
57
58 26
59
60

6H), 1.88 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.2, 139.8, 138.0, 131.1, 129.0, 128.5, 127.7, 123.8, 105.7, 21.2, 13.6, 11.1; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{14}\text{H}_{15}\text{N}_2$ 213.1392; found 213.1376.

General procedure for the synthesis of (*E*)-styryl pyrazoles (4a–g): In an oven dried pressure tube, to a solution of pyrazoles **1a** and **1i–j** (0.5 mmol) in DMSO, finely crushed KOH (2.0 equiv) and alkynes **2a–b**, **2n–2p** and **2q** (1.0 mmol) were added under inert atmosphere. The resulting reaction mixture was heated at 120 °C for 24 h. Progression of the reaction was monitored by TLC, while noticing complete consumption of alkynes, reaction was brought to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel mesh size 100–200 (hexane).

(E)-1-Styryl-1H-pyrazole (**4a**). The product was obtained as a yellow semi-solid (57.8 mg, 68% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.60–7.59 (m, 2H), 7.44 (d, $J = 14.5$ Hz, 1H), 7.36–7.34 (m, 2H), 7.27 (t, $J = 7.6$ Hz, 2H), 7.20–7.16 (m, 1H), 6.97 (d, $J = 14.5$ Hz, 1H), 6.33–6.32 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.1, 134.9, 128.8, 128.0, 127.5, 126.3, 126.1, 116.9, 107.3; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{11}\text{H}_{11}\text{N}_2$ 171.0922; found 171.0915.

(E)-1-(4-Methylstyryl)-1H-pyrazole (**4b**). The product was obtained as a yellow semi-solid (64.4 mg, 70% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.59–7.58 (m, 2H), 7.41 (d, $J = 14.5$ Hz, 1H), 7.25 (d, $J = 8.3$ Hz, 2H), 7.08 (d, $J = 7.6$ Hz, 2H), 6.95 (d, $J = 14.5$ Hz, 1H), 6.32–6.31 (m, 1H), 2.28 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.9, 137.5, 132.1, 129.5, 127.8, 126.1, 125.7, 116.9, 107.1, 21.2; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2$ 185.1079; found 185.1080.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-1-(4-Bromostyryl)-1*H*-pyrazole (**4c**). The product was obtained as a yellow semi-solid (80.2 mg, 65% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, *J* = 1.5 Hz, 1H), 7.64 (d, *J* = 2.2 Hz, 1H), 7.50–7.47 (m, 2H), 7.44 (s, 1H), 7.27 (d, *J* = 8.3 Hz, 2H), 6.99 (d, *J* = 14.5 Hz, 1H), 6.40–6.39 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 141.3, 134.0, 131.9, 128.1, 127.6, 126.7, 121.2, 115.7, 107.5; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₁H₁₀BrN₂ 249.0027; found 249.0051.

(*E*)-1-(3,5-Dimethoxystyryl)-1*H*-pyrazole (**4d**). The product was obtained as a yellow oil (78.2 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.60–7.58 (m, 1H), 7.51 (s, 1H), 7.43 (d, *J* = 14.5 Hz, 1H), 7.30–7.29 (m, 1H), 6.51–6.50 (m, 1H), 6.32–6.30 (m, 1H), 6.269–6.263 (m, 1H), 6.14–6.12 (m, 1H), 3.73 (s, 3H), 3.63 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 140.3, 136.1, 129.8, 127.2, 119.1, 106.3, 104.2, 100.3, 55.3; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₃H₁₅N₂O₂ 231.1134; found 231.1135.

(*E*)-1-(2-(Phenanthren-9-yl)vinyl)-1*H*-pyrazole (**4e**). The product was obtained as orange needles (89.1 mg, 66% yield), mp 91–94 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.65 (d, *J* = 7.7 Hz, 1H), 8.58 (d, *J* = 8.2 Hz, 1H), 8.13 (d, *J* = 7.7 Hz, 1H), 7.81–7.78 (m, 2H), 7.72 (d, *J* = 13.7 Hz, 1H), 7.666–7.660 (m, 2H), 7.63–7.61 (m, 1H), 7.59–7.58 (m, 1H), 7.56 (s, 1H), 7.54–7.51 (m, 1H), 7.48 (d, *J* = 14.2 Hz, 1H), 6.37–6.36 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 141.3, 131.7, 131.4, 130.7, 130.4, 130.3, 128.6, 128.4, 126.9, 126.8, 126.73, 126.66, 124.8, 124.5, 123.1, 122.5, 114.8, 107.4; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₉H₁₅N₂ 271.1235; found 271.1231.

(*E*)-4-Bromo-1-(4-(trifluoromethyl)styryl)-1*H*-pyrazole (**4f**). The product was obtained as a yellow solid (100.8 mg, 64% yield), mp: 90–92 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.64 (s,

1
2
3 1H), 7.56 (s, 1H), 7.53–7.51 (m, 2H), 7.42 (s, 1H), 7.41–7.40 (m, 1H), 7.38 (s, 1H), 6.94 (d, J =
4 14.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 142.1, 138.2, 129.8, 129.5, 128.1, 127.6, 126.4,
5
6 125.8 (q, J = 3.8 Hz, 1C), 116.1, 95.9; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for $\text{C}_{12}\text{H}_9\text{BrF}_3\text{N}_2$
7
8 316.9901; found 316.9897.
9
10
11

12
13 (*E*)-4-Bromo-3,5-dimethyl-1-(4-(trifluoromethyl)styryl)-1H-pyrazole (**4g**). The product
14 was obtained as a yellow semi-solid (106.6 mg, 62% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.51
15 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 13.7 Hz, 1H), 7.15 (d, J = 13.4 Hz, 1H),
16 2.30 (s, 3H), 2.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.2, 139.0, 137.6, 128.1, 127.6,
17 126.2, 125.7 (q, J = 3.9 Hz, 1C), 124.3, 115.7, 97.0, 12.5, 10.3; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$
18
19 Calcd for $\text{C}_{14}\text{H}_{13}\text{BrF}_3\text{N}_2$ 345.0214; found 345.0224.
20
21
22
23
24
25
26
27

28
29 (*E*)-1-(4-(Trifluoromethyl)styryl)-1H-pyrazole (**4h**). The product was obtained as a white solid
30 (53.75 mg, 45% yield), mp: 100–102 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.69–7.67 (m, 2H),
31 7.60–7.58 (m, 2H), 7.55–7.49 (m, 3H), 7.08 (d, J = 14.2 Hz, 1H), 6.42 (t, J = 1.83 Hz, 1H); ^{13}C
32 NMR (100 MHz, CDCl_3) δ 141.6, 138.7, 129.4, 129.1, 128.4, 128.0, 126.2, 125.80–125.70 (m,
33 1C), 122.8, 115.3, 107.3; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for $\text{C}_{12}\text{H}_{10}\text{F}_3\text{N}_2$ 239.0796; found
34 239.0794.
35
36
37
38
39
40
41
42

43
44 (*E*)-1-(4-Nitrostyryl)-1H-pyrazole (**4i**). The product was obtained as a dark yellow solid (53.55
45 mg, 50% yield), mp: 190–192 °C, ^1H NMR (400 MHz, CDCl_3) δ 8.22–8.20 (m, 2H), 7.718–
46 7.714 (m, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.64 (d, J = 14.2 Hz, 1H), 7.56–7.54 (m, 2H), 7.12 (d, J
47 = 14.6 Hz, 1H), 6.45 (t, J = 1.83 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 146.8, 142.2, 142.0,
48 129.4, 128.8, 126.5, 124.3, 114.5, 108.2; HRMS (EI-TOF) m/z : (M) $^+$ Calcd for $\text{C}_{11}\text{H}_9\text{N}_3\text{O}_2$
49 215.0676; found 215.0676.
50
51
52
53
54
55
56
57

1
2
3 **General procedure for the synthesis of *N*-styryl pyrazoles (5a–m):** In an oven dried pressure
4 tube, to a solution of pyrazoles **1a**, **1d** and **1f** (0.5 mmol) in DMSO, finely crushed KOH (1.0
5 equiv) and alkynes **2aa–2ak** (1.0 mmol) were added under inert atmosphere. The resulting
6 reaction mixture was heated at 120 °C for 4–5 h. Progression of the reaction was monitored by
7 TLC, while noticing complete consumption of alkynes, reaction was brought to room
8 temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL).
9 Organic layer was concentrated under reduced pressure. The crude material so obtained was
10 purified by column chromatography on silica gel mesh size 100–200 (hexane).
11
12
13
14
15
16
17
18
19
20
21
22

23 *(Z)*-1-(3-Phenylprop-1-en-1-yl)-1*H*-pyrazole (**5a**). The product was obtained as a pale
24 yellow oil (57.0 mg, 62% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.73–7.72 (m, 1H), 7.65 (s, 1H),
25 7.37–7.31 (m, 5H), 7.25–7.22 (m, 1H), 7.06 (s, 1H), 6.36–6.35 (m, 1H), 2.41 (s, 2H); ¹³C NMR
26 (100 MHz, CDCl₃) δ 140.1, 135.8, 135.5, 129.0, 128.2, 126.8, 126.7, 117.0, 106.5, 15.6 ; HRMS
27 (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₂H₁₃N₂ 185.1079; found 185.1096.
28
29
30
31
32
33
34
35

36 *(Z)*-1-(4-Phenylbut-1-en-1-yl)-1*H*-pyrazole (**5b**). The product was obtained as a reddish
37 oil (59.4 mg, 60% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, 1H), 7.38–7.36 (m, 1H), 7.31–
38 7.28 (m, 3H), 7.27–7.25 (m, 1H), 7.22–7.21 (m, 1H), 6.42–6.38 (m, 1H), 6.23–6.22 (m, 1H),
39 6.14–6.07 (m, 1H), 4.25 (t, *J* = 7.2 Hz, 2H), 2.78 (q, *J* = 6.6 Hz, 2H); ¹³C NMR (100 MHz,
40 CDCl₃) δ 139.4, 137.1, 132.7, 129.1, 128.5, 127.3, 126.1, 125.6, 105.3, 51.9, 34.0; HRMS
41 (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₃H₁₅N₂ 199.1235; found 199.1230.
42
43
44
45
46
47
48
49
50

51 *(Z)*-3-(1*H*-pyrazol-1-yl)prop-2-en-1-ol (**5c**). The product was obtained as a yellow oil
52 (42.1 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.74–7.72 (m, 1H), 7.536–7.532 (m, 1H),
53 6.29–6.28 (m, 1H), 5.22 (s, 1H), 4.86 (m, 1H), 4.48–4.47 (m, 2H), 4.30 (br s, 1H); ¹³C NMR
54
55
56
57
58
59
60

(100 MHz, CDCl₃) δ 141.5, 130.7, 127.4, 117.4, 106.8, 56.8; HRMS (ESI-TOF) m/z : (M+H)⁺
Calcd for C₆H₉N₂O 125.0715; found 125.0716.

(*Z*)-6-(1*H*-Pyrazol-1-yl)hex-5-en-1-ol (**5d**). The product was obtained as a green oil (48.1 mg, 58% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.71–7.61 (m, 2H), 6.349–6.345 (m, 1H), 5.25 (s, 1H), 4.74 (s, 1H), 3.74–3.67 (m, 3H), 2.72–2.69 (m, 2H), 1.77–1.73 (m, 2H), 1.33–1.23 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 145.6, 140.3, 127.1, 116.8, 106.8, 62.3, 32.2, 31.7, 23.6; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd for C₉H₁₅N₂O 167.1184; found 167.1182.

(*Z*)-1-(2-(1*H*-Pyrazol-1-yl)vinyl)cyclopentanol (**5e**). The product was obtained as a brown oil (48.9 mg, 55% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, 1H), 7.41 (s, 1H), 6.92 (s, 1H), 6.54 (d, *J* = 10.6 Hz, 1H), 6.27 (s, 1H), 5.39 (d, *J* = 10.6 Hz, 1H), 2.00–1.96 (m, 2H), 1.83 (s, 2H), 1.59–1.56 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 140.9, 131.2, 125.6, 123.7, 106.5, 78.5, 41.3, 23.5; HRMS (ESI-TOF) m/z : (M+Na)⁺ Calcd for C₁₀H₁₄N₂ONa 201.1004; found 201.0980.

(*Z*)-1-(2-(1*H*-Pyrazol-1-yl)vinyl)cyclohexanol (**5f**). The product was obtained as a brown oil (57.6 mg, 60% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 7.417–7.412 (m, 1H), 7.14 (s, 1H), 6.52 (d, *J* = 10.6 Hz, 1H), 6.26–6.25 (m, 1H), 5.25 (d, *J* = 10.6 Hz, 1H), 1.73–1.63 (m, 4H), 1.66–1.55 (m, 2H), 1.41–1.27 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 140.7, 131.3, 125.8, 123.0, 106.5, 69.4, 38.4, 25.6, 22.3; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd for C₁₁H₁₇N₂O 193.1341; found 193.1336.

(*Z*)-1-(3-Methoxyprop-1-en-1-yl)-1*H*-pyrazole (**5g**). The product was obtained as a yellow oil (46.9 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.62 (s, 1H), 7.53–7.52 (m, 1H), 6.82–6.79 (m, 1H), 6.33–6.32 (m, 1H), 5.37–5.35 (m, 1H), 4.44 (d, *J* = 6.1 Hz, 2H), 3.38 (m,

3H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0, 130.3, 126.3, 116.3, 106.6, 68.6, 58.3; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_7\text{H}_{11}\text{N}_2\text{O}$ 139.0871; found 139.0879.

(Z)-1-(3-Phenoxyprop-1-en-1-yl)-1H-pyrazole (5h). The product was obtained as a yellow oil (60.0 mg, 60% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.59–7.55 (m, 1H), 7.53–7.52 (m, 1H), 7.33 (d, $J = 8.3$ Hz, 1H), 7.23 (t, $J = 8.3$ Hz, 1H), 7.15–7.10 (m, 2H), 7.05 (t, $J = 7.6$ Hz, 1H), 6.92–6.87 (m, 2H), 6.29–6.21 (m, 1H), 4.62–4.61 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.2, 140.1, 134.5, 129.6, 122.9, 120.7, 116.1, 114.7, 106.1, 64.4; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}$ 201.1028; found 201.1054.

(Z)-3-(3-(Trifluoromethyl)-1H-pyrazol-1-yl)prop-2-en-1-ol (5i). The product was obtained as a brown oil (66.2 mg, 69% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.53–7.52 (m, 1H), 6.74 (d, $J = 9.9$ Hz, 1H), 6.56–6.55 (m, 1H), 5.67–5.61 (m, 1H), 4.34 (d, $J = 7.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.4, 144.0, 131.9, 126.4, 121.1, 105.3, 57.1; HRMS (ESI-TOF) m/z : $(\text{M}+\text{Na})^+$ Calcd for $\text{C}_7\text{H}_7\text{F}_3\text{N}_2\text{ONa}$ 215.0408; found 215.0417.

(Z)-1-(4-Phenylbut-1-en-1-yl)-3-(trifluoromethyl)-1H-pyrazole (5j). The product was obtained as a pale white oil (78.4 mg, 59% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.33 (s, 1H), 7.19–7.16 (m, 2H), 7.13–7.11 (m, 2H), 7.06 (d, $J = 7.6$ Hz, 2H), 6.36 (s, 1H), 6.05 (q, $J = 21.3$ Hz, 1H), 3.95 (s, 2H), 1.86 (d, $J = 6.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 137.7, 137.1, 129.2, 128.7, 128.5, 128.0, 126.7, 122.6, 117.9, 104.4, 34.1, 29.7; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{14}\text{H}_{14}\text{F}_3\text{N}_2$ 267.1109; found 267.1113.

(Z)-4-Bromo-1-(hex-1-en-1-yl)-1H-pyrazole (5k). The product was obtained as a yellow oil (45.6 mg, 40% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.61 (s, 1H), 7.48 (s, 1H), 5.18 (s, 1H), 4.67 (s, 1H), 2.53 (t, $J = 7.6$ Hz, 2H), 1.47–1.39 (m, 2H), 1.35–1.26 (m, 2H), 0.85 (t, $J = 7.6$ Hz, 3H)

3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.4, 140.6, 127.1, 100.5, 94.6, 32.0, 29.3, 22.2, 13.8; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_9\text{H}_{14}\text{BrN}_2$ 229.0340; found 229.0326.

(Z)-5-(4-Bromo-1H-pyrazol-1-yl)pent-4-en-1-ol (**5l**). The product was obtained as a brown semi-solid (69.0 mg, 60% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.75 (s, 1H), 7.56 (s, 1H), 5.24 (s, 1H), 4.80 (s, 1H), 3.67 (t, $J = 6.1$ Hz, 2H), 2.76 (t, $J = 7.6$ Hz, 2H), 1.84–1.78 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.1, 140.7, 134.3, 127.3, 100.9, 62.1, 31.7, 23.5; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_8\text{H}_{12}\text{BrN}_2\text{O}$ 231.0133; found 231.0130.

(E)-Ethyl 3-(1H-pyrazol-1-yl)acrylate (**5m**). The product was obtained as a light brown semi-solid (54.7 mg, 66% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, $J = 13.7$ Hz, 1H), 7.67 (s, 1H), 7.62 (d, $J = 2.2$ Hz, 1H), 6.40–6.39 (m, 1H), 6.31 (d, $J = 13.7$ Hz, 1H), 4.21 (q, $J = 7.6$ Hz, 2H), 1.27 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.5, 143.4, 139.5, 130.0, 109.0, 105.7, 60.5, 14.2; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_8\text{H}_{11}\text{N}_2\text{O}_2$ 167.0821; found 167.0842.

General procedure for the synthesis of *N*-styryl pyrazoles (7a–k**):** In an oven dried pressure tube, to a solution of pyrazoles **1a–b**, **1d** and **1f** (0.5 mmol) in DMSO, finely crushed KOH (1.5 equiv) and alkynes **6a–h** (0.5 mmol) were added under inert atmosphere. The resulting reaction mixture was heated at 120 °C for 24 h. Progression of the reaction was monitored by TLC, while noticing complete consumption of alkynes, reaction was brought to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel mesh size 100–200 (hexane).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*Z*)-1-(1,2-Diphenylvinyl)-1*H*-pyrazole (**7a**). The product was obtained as a yellow semi-solid (86.1 mg, 70% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.697–7.694 (m, 1H), 7.30–7.29 (m, 1H), 7.28–7.25 (m, 3H), 7.16–7.15 (m, 1H), 7.14–7.13 (m, 2H), 7.12–7.11 (m, 2H), 6.94 (s, 1H), 6.75–6.72 (m, 2H), 6.32–6.31 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 140.7, 138.0, 137.4, 134.0, 131.5, 128.7, 128.6, 128.4, 128.2, 127.8, 125.9, 124.6, 106.6; HRMS (ESI-TOF) *m/z*: (M+Na)⁺ Calcd for C₁₇H₁₄N₂Na 269.1055; found 269.1048.

(*Z*)-1-(1,2-Di-*p*-tolylvinyl)-1*H*-pyrazole (**7b**). The product was obtained as a pale white oil (93.1 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.37–7.36 (m, 1H), 7.14–7.08 (m, 4H), 6.99 (d, *J* = 7.7 Hz, 2H), 6.93 (s, 1H), 6.67 (d, *J* = 8.2 Hz, 2H), 6.38–6.37 (m, 1H), 2.34 (s, 3H), 2.27 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 140.8, 138.7, 137.9, 137.4, 135.0, 131.6, 131.5, 129.2, 129.1, 128.7, 125.9, 124.0, 106.7, 21.2; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₉H₁₉N₂ 275.1548; found 275.1545.

(*Z*)-1-(2-(*m*-Tolyl)-1-(*p*-tolyl)vinyl)-1*H*-pyrazole (**7c**). The product was obtained as a pale yellow oil (89.0 mg, 65% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.77–7.76 (m, 1H), 7.16–7.12 (m, 3H), 7.10–7.05 (m, 1H), 7.01–6.97 (m, 3H), 6.94–6.92 (m, 1H), 6.68 (d, *J* = 8.7 Hz, 1H), 6.60–6.57 (m, 1H), 6.40–6.38 (m, 1H), 2.28 (s, 3H), 2.21 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 140.7, 138.9, 134.9, 134.2, 131.5, 129.6, 129.3, 128.7, 128.2, 126.0, 125.8, 124.9, 124.1, 123.2, 106.6, 21.3, 21.2; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₉H₁₉N₂ 275.1548; found 275.1545.

(*Z*)-1-(2-(4-Bromophenyl)-1-(*p*-tolyl)vinyl)-1*H*-pyrazole (**7d**). The product was obtained as yellow semi-solid (119.9 mg, 71% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.69–7.67 (m, 1H), 7.29–7.22 (m, 3H), 7.09–7.02 (m, 4H), 6.80 (s, 1H), 6.56 (d, *J* = 8.3 Hz, 2H), 6.33–6.32 (m, 1H),

2.28 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0, 138.8, 133.3, 131.7, 131.5, 130.2, 129.3, 129.2, 128.8, 127.5, 126.1, 122.5, 121.8, 107.0, 21.3; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{18}\text{H}_{16}\text{BrN}_2$ 339.0497; found 339.0495.

(Z)-1-(2-(4-Nitrophenyl)-1-phenylvinyl)-1H-pyrazole (**7e**). The product was obtained as a yellow solid (101.8 mg, 70% yield), mp: 120–122 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, J = 8.4 Hz, 2H), 7.72 (s, 1H), 7.51–7.42 (m, 3H), 7.37 (s, 1H), 7.33–7.31 (m, 2H), 7.21 (d, J = 2.2 Hz, 1H), 7.07 (d, J = 9.1 Hz, 2H), 6.33–6.32 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.9, 142.4, 141.7, 141.2, 133.2, 130.3, 130.2, 129.64, 129.58, 129.5, 123.4, 116.0, 107.3; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{17}\text{H}_{14}\text{N}_3\text{O}_2$ 292.1086; found 292.1079.

(Z)-1-(1,2-Di(thiophen-3-yl)vinyl)-1H-pyrazole (**7f**). The product was obtained as a dark brown semi-solid (79.9 mg, 62% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.79–7.78 (m, 1H), 7.45–7.44 (m, 1H), 7.29–7.27 (m, 1H), 7.16–7.14 (m, 1H), 7.10–7.08 (m, 1H), 7.06 (s, 1H), 6.82 (dd, J = 12.2 and 1.5 Hz, 2H), 6.45–6.44 (m, 1H), 6.13 (d, J = 4.5 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.7, 139.9, 135.0, 132.6, 131.0, 127.1, 126.5, 125.7, 125.5, 124.5, 122.4, 119.3, 106.8; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{13}\text{H}_{11}\text{N}_2\text{S}_2$ 259.0364; found 259.0362.

(Z)-1-(1-Phenylprop-1-en-2-yl)-1H-pyrazole (**7g**). The product was obtained as a yellow liquid (66.2 mg, 72% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.72–7.71 (m, 1H), 7.66 (s, 1H), 7.37–7.31 (m, 4H), 7.25–7.24 (m, 1H), 7.08 (s, 1H), 6.36–6.35 (m, 1H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.1, 135.8, 135.5, 129.0, 128.2, 126.8, 126.7, 116.9, 106.5, 15.6; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2$ 185.1079; found 185.1074.

(Z)-3-Phenyl-2-(1H-pyrazol-1-yl)prop-2-en-1-ol (**7h**). The product was obtained as a yellow liquid (65.0 mg, 65% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.58–7.57 (m, 1H), 7.479–

1
2
3 7.473 (m, 1H), 7.10–7.09 (m, 2H), 6.77–6.74 (m, 2H), 6.51 (s, 1H), 6.32 (br s, 1H), 6.21 (t, $J =$
4
5 3.8 Hz, 1H), 6.16–6.15 (m, 1H), 4.46 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.4, 137.8,
6
7 133.6, 131.0, 128.5, 127.8, 122.4, 106.4, 104.8, 64.5; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for
8
9 $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}$ 201.1028; found 201.1022.

10
11
12
13
14 *(Z)*-3-Methyl-1-(1-phenylprop-1-en-2-yl)-1H-pyrazole (**7i**). The product was obtained
15
16 as a pale/light yellow semi-solid (68.3 mg, 69% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.557–
17
18 7.553 (m, 1H), 7.29–7.23 (m, 4H), 7.18–7.16 (m, 1H), 6.97 (s, 1H), 6.09–6.08 (m, 1H), 2.31 (s,
19
20 3H), 2.28 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.9, 136.2, 135.3, 129.1, 128.2, 127.6,
21
22 126.6, 116.0, 106.5, 15.6, 13.8; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for $\text{C}_{13}\text{H}_{15}\text{N}_2$ 199.1235;
23
24 found 199.1204.
25
26

27
28
29 *(Z)*-1-(1,2-Diphenylvinyl)-3-(trifluoromethyl)-1H-pyrazole (**7j**). The product was obtained
30
31 as a white oil (102.0 mg, 65% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.33–7.25 (m, 4H), 7.17–
32
33 7.12 (m, 5H), 7.04 (s, 1H), 6.74–6.72 (m, 2H), 6.57 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ
34
35 137.5, 136.6, 133.6, 133.5, 132.4, 131.6, 130.1, 129.3, 128.8, 128.7, 128.61, 128.55, 128.3,
36
37 126.3, 125.9, 105.3; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for $\text{C}_{18}\text{H}_{14}\text{F}_3\text{N}_2$ 315.1109; found
38
39 315.1111.
40
41

42
43 *(Z)*-4-Bromo-1-(1,2-diphenylvinyl)-1H-pyrazole (**7k**). The product was obtained as a
44
45 pale/light yellow semi-solid (102.0 mg, 63% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.64 (s, 1H),
46
47 7.33 (s, 1H), 7.31–7.28 (m, 3H), 7.18–7.14 (m, 5H), 6.93 (s, 1H), 6.79–6.77 (m, 2H); ^{13}C NMR
48
49 (100 MHz, CDCl_3) δ 141.5, 137.6, 137.0, 133.8, 131.7, 129.2, 128.8, 128.7, 128.6, 128.4, 126.1,
50
51 125.3, 94.5; HRMS (ESI-TOF) m/z : ($\text{M}+\text{Na}$) $^+$ Calcd for $\text{C}_{17}\text{H}_{13}\text{BrN}_2\text{Na}$ 347.0160; found
52
53 347.0147.
54
55
56
57
58
59
60

General procedure for the synthesis of *N*-styryl benzpyrazoles (8a–g): In an oven dried pressure tube, to a solution of pyrazoles **1k–l** (0.5 mmol) in DMSO, finely crushed KOH (1.0 equiv) and alkynes **2a–c**, **2h**, **2n** and **6a** (1.0 mmol) were added under inert atmosphere. The resulting reaction mixture was heated at 120 °C for 8–36 h. Progression of the reaction was monitored by TLC, while noticing complete consumption of alkynes, reaction was brought to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel mesh size 100–200 (hexane).

(Z)-5-Bromo-1-styryl-1*H*-indazole (**8a**). The product was obtained as a yellow oil (96.8 mg, 65% yield), ¹H NMR (400 MHz, CDCl₃) δ 8.06–8.05 (m, 1H), 7.838–7.832 (m, 1H), 7.248–7.244 (m, 1H), 7.15–7.13 (m, 3H), 7.05 (d, *J* = 9.7 Hz, 1H), 7.02–7.00 (m, 2H), 6.85 (d, *J* = 9.1 Hz, 1H), 6.48 (d, *J* = 9.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 137.4, 136.4, 134.8, 134.1, 129.8, 128.8, 128.3, 128.1, 123.74, 123.67, 123.3, 114.6, 112.4; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₅H₁₂BrN₂ 299.0184; found 299.0210

(Z)-5-Bromo-1-(4-methylstyryl)-1*H*-indazole (**8b**). The product was obtained as a yellow semi-solid (98.2 mg, 63%), ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.78 (s, 1H), 7.23–7.21 (m, 1H), 6.94 (d, *J* = 9.1 Hz, 1H), 6.90–6.88 (m, 2H), 6.85–6.83 (m, 3H), 6.41 (d, *J* = 9.1 Hz, 1H), 2.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 140.8, 139.3, 134.7, 129.8, 129.0, 128.7, 128.4, 124.2, 123.3, 123.0, 118.1, 112.4, 21.3; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₆H₁₄BrN₂ 313.0340; found 313.0338.

(Z)-5-Bromo-1-(4-bromostyryl)-1*H*-indazole (**8c**). The product was obtained as a dark brown semi-solid (125.6 mg, 67% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.77 (s, 1H), 7.71 (s, 1H), 7.58 (d, *J* = 9.1 Hz, 1H), 7.42 (d, *J* = 8.3 Hz, 2H), 7.35–7.33 (m, 1H), 7.22 (d, *J* = 9.9 Hz,

1
2
3 1H), 7.02 (d, $J = 8.3$ Hz, 2H), 6.49 (d, $J = 9.1$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 139.1,
4
5 135.8, 133.4, 133.1, 131.4, 130.5, 130.3, 125.4, 123.5, 122.2, 121.64, 121.58, 113.5; HRMS
6
7 (EI-TOF) m/z : (M) $^+$ Calcd for $\text{C}_{15}\text{H}_{10}\text{Br}_2\text{N}_2$ 375.9211; found 375.9217.

8
9
10 (*Z*)-5-Bromo-1-(2-(thiophen-3-yl)vinyl)-1H-indazole (**8d**). The product was obtained as a
11
12 brown semi-solid (90.9 mg, 60% yield), ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 7.82–7.81
13
14 (m, 1H), 7.30 (dd, $J = 9.1$ and 1.8 Hz, 1H), 7.15–7.14 (m, 1H), 7.03–7.01 (m, 1H), 6.97 (d, $J =$
15
16 8.5 Hz, 1H), 6.88 (d, $J = 8.5$ Hz, 1H), 6.56–6.53 (m, 1H), 6.48 (d, $J = 9.1$ Hz, 1H); ^{13}C NMR
17
18 (100 MHz, CDCl_3) δ 138.0, 134.9, 134.6, 130.0, 128.0, 126.0, 125.7, 125.3, 123.4, 122.1, 119.1,
19
20 114.7, 112.1; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for $\text{C}_{13}\text{H}_{10}\text{BrN}_2\text{S}$ 304.9748; found
21
22 304.9737.
23
24
25

26
27 (*Z*)-6-Bromo-1-styryl-1H-indole (**8e**). The product was obtained as a dark brown semi-solid
28
29 (92.3 mg, 62% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.83–7.81 (m, 1H), 7.73 (s, 1H), 7.43 (d, J
30
31 = 4.8 Hz, 1H), 7.30 (d, $J = 8.5$ Hz, 1H), 7.22–7.21 (m, 2H), 7.14–7.10 (m, 1H), 7.08–7.02 (m,
32
33 3H), 6.50 (d, $J = 8.5$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 142.0, 138.8, 133.5, 128.8, 128.6,
34
35 127.1, 126.7, 126.2, 124.0, 123.9, 121.8, 120.0, 117.8; HRMS (ESI-TOF) m/z : ($\text{M}+\text{H}$) $^+$ Calcd for
36
37 $\text{C}_{15}\text{H}_{12}\text{BrN}_2$ 299.0184; found 299.0203.
38
39
40

41
42 (*Z*)-6-Bromo-1-(4-ethylstyryl)-1H-indazole (**8f**). The product was obtained as a dark brown
43
44 semi-solid (97.8 mg, 60% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.87 (d, $J = 11.4$ Hz, 2H), 7.39
45
46 (d, $J = 8.3$ Hz, 1H), 7.15–7.09 (m, 4H), 7.05–7.03 (m, 2H), 6.53 (d, $J = 9.1$ Hz, 1H), 2.62 (q, $J =$
47
48 7.6 Hz, 2H), 1.22 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.6, 144.9, 130.6, 128.6,
49
50 128.3, 126.4, 126.1, 124.4, 123.9, 121.8, 120.8, 120.3, 120.0, 28.6, 15.3; HRMS (ESI-TOF) m/z :
51
52 ($\text{M}+\text{H}$) $^+$ Calcd for $\text{C}_{17}\text{H}_{16}\text{BrN}_2$ 327.0497; found 327.0491.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*Z*)-6-Bromo-1-(1,2-diphenylvinyl)-1*H*-indazole (**8g**). The product was obtained as a dark brown semi-solid (114.0 mg, 61% yield), ¹H NMR (400 MHz, CDCl₃) δ 8.12 (s, 1H), 7.86 (d, *J* = 26.7 Hz, 1H), 7.51 (d, *J* = 9.1 Hz, 1H), 7.24–7.22 (m, 4H), 7.13–7.06 (m, 4H), 7.00–6.98 (m, 2H), 6.68–6.63 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 140.5, 137.4, 135.8, 135.7, 134.2, 129.0, 128.7, 128.5, 128.4, 128.2, 126.5, 126.1, 125.0, 123.1, 122.0, 121.3, 113.6; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₂₁H₁₆BrN₂ 375.0497; found 375.0479.

General procedure for the synthesis of bis-hydroaminated-heterocycles (9a–e): In an oven dried pressure tube, to a solution of *N*-heterocycles **1a**, **1l** and **1m–o** (0.5 mmol) each in DMSO, finely crushed KOH (1.0 equiv) and alkynes **2r–s** (0.25 mmol) were added under inert atmosphere. The resulting reaction mixture was heated at 120 °C for 0.5 h–2 h. Progression of the reaction was monitored by TLC, while noticing complete consumption of alkynes, reaction was brought to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL) and water (15 mL). Organic layer was concentrated under reduced pressure. The crude material so obtained was purified by column chromatography on silica gel mesh size 100–200 (hexane).

*1,3-Bis((Z)-2-(4-iodo-1*H*-pyrazol-1-yl)vinyl)benzene (9a)*. The product was obtained as a yellow oil (148.7 mg, 58%), ¹H NMR (400 MHz, CDCl₃) δ 7.49 (s, 2H), 7.26 (s, 2H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.01 (d, *J* = 7.6 Hz, 2H), 6.94 (s, 1H), 6.83 (d, *J* = 9.9 Hz, 2H), 6.12 (d, *J* = 9.9 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 145.2, 134.2, 133.6, 132.3, 129.0, 128.2, 126.4, 119.8, 119.5, 58.2; HRMS (ESI-TOF) *m/z*: (M+H)⁺ Calcd for C₁₆H₁₃I₂N₄ 514.9230; found 514.9233.

*1,4-Bis((Z)-2-(6-bromo-1*H*-indazol-1-yl)vinyl)benzene (9b)*. The product was obtained as a yellow solid (116.3 mg, 45%), mp: 100–101 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.07 (s, 2H), 7.69 (s, 2H), 7.63 (d, *J* = 8.3 Hz, 2H), 7.30–7.27 (m, 3H), 7.22 (d, *J* = 6.8 Hz, 3H), 6.92 (s, 2H),

6.86 (d, $J = 8.3$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.3, 134.9, 133.3, 128.8, 125.0, 124.7, 122.5, 122.0, 121.3, 117.9, 117.0, 112.7; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{24}\text{H}_{17}\text{Br}_2\text{N}_4$ 518.9820; found 518.9812.

1-((Z)-3-((Z)-2-(1H-pyrazol-1-yl)vinyl)styryl)-1H-1,2,4-triazole (9c). The product was obtained as a yellow oil (77.5 mg, 59%), ^1H NMR (400 MHz, CDCl_3) δ 7.93 (d, $J = 10.3$ Hz, 2H), 7.53 (s, 1H), 7.24–7.14 (m, 2H), 7.09 (d, $J = 7.6$ Hz, 1H), 6.97–6.93 (m, 3H), 6.88 (dd, $J = 9.1$ and 2.2 Hz, 1H), 6.42 (d, $J = 9.9$ Hz, 1H), 6.16–6.12 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.6, 140.3, 135.1, 133.5, 129.4, 129.3, 129.0, 128.7, 127.4, 127.1, 123.6, 123.3, 118.2, 106.7; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_5$ 264.1249; found 264.1242.

1-((Z)-4-((Z)-2-(1H-Pyrazol-1-yl)vinyl)styryl)-1H-indole (9d). The product was obtained as a white solid (91.7 mg, 59%), mp: 100–101 °C, ^1H NMR (400 MHz, CDCl_3) δ 7.65–7.51 (m, 1H), 7.58 (d, $J = 7.6$ Hz, 1H), 7.35–7.31 (m, 1H), 7.29 (d, $J = 7.6$ Hz, 1H), 7.25–7.22 (m, 1H), 7.20–7.15 (m, 2H), 7.11–7.09 (m, 2H), 7.06–7.04 (m, 3H), 6.96 (d, $J = 11.4$ Hz, 2H), 6.53–6.51 (m, 1H), 6.27–6.24 (m, 1H), 6.20–6.17 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.2, 140.4, 135.6, 134.5, 133.4, 129.5, 129.1, 128.8, 128.5, 126.9, 126.1, 123.7, 122.4, 120.9, 120.7, 119.2, 118.9, 116.3, 110.2, 106.7, 104.1; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{21}\text{H}_{18}\text{N}_3$ 312.1501; found 312.1498.

(Z)-1-(2,4-Bis(4-methoxyphenyl)but-1-en-3-yn-1-yl)-1H-pyrazole (9e). The product was obtained as a yellow semi-solid (79.2 mg, 48% yield), ^1H NMR (400 MHz, CDCl_3) δ 8.17–8.16 (m, 1H), 7.727–7.723 (m, 1H), 7.28 (d, $J = 8.3$ Hz, 2H), 7.21 (d, $J = 8.3$ Hz, 2H), 6.88 (d, $J = 9.1$ Hz, 2H), 6.82 (d, $J = 8.3$ Hz, 2H), 6.46 (t, $J = 2.2$ Hz, 1H), 5.97 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.7, 159.7, 146.5, 140.7, 132.9, 132.1, 128.74, 128.68,

1
2
3 115.2, 114.0, 113.9, 105.8, 99.3, 95.3, 84.9, 55.34, 55.26; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd
4 for C₂₁H₁₉N₂O₂ 331.1447; found 331.1447.
5
6

7
8
9 **General procedure for the synthesis of deuterated *N*-styryl pyrazoles (10a–e & 10h):** In
10 an oven dried pressure tube, to a solution of pyrazoles **1a** (0.5 mmol) in DMSO-d₆, finely
11 crushed KOH (0.5–2.0 equiv) and alkynes **2b**, **2ac** and **6b** (1.0 mmol) were added under inert
12 atmosphere. The resulting reaction mixture was heated at 120 °C for 0.5 h–24 h. Progression of
13 the reaction was monitored by TLC, while noticing complete consumption of alkynes, reaction
14 was brought to room temperature. The reaction mixture was diluted with ethyl acetate (10 mL)
15 and water (15 mL). Organic layer was concentrated under reduced pressure. The crude material
16 so obtained was purified by column chromatography on silica gel mesh size 100–200 (hexane).
17
18

19
20
21
22
23
24
25
26
27
28
29 *(Z)*-1-Styryl-1*H*-pyrazole (**10a**). The product was obtained as a yellow semi-solid (60.2 mg,
30 70% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.59–7.58 (m, 1H), 7.31–7.24 (m, 4H), 7.20–7.18 (m,
31 2H), 6.18–6.17 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 139.9, 134.0, 129.1, 128.3, 128.2, 127.5,
32 126.6–126.5 (m, 1C), 118.6–118.3 (m, 1C), 106.3; HRMS (ESI-TOF) m/z : (M+H)⁺ Calcd for
33 C₁₁H₉D₂N₂ 173.1048; found 173.1037.
34
35
36
37
38
39

40
41
42 *(Z)*-1-(4-Methylstyryl)-1*D*-pyrazole (**10b**). The product was obtained as a orange semi-solid
43 (63.2 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, 1H), 7.347–7.341 (m, 1H), 7.11–
44 7.06 (m, 4H), 6.20–6.19 (m, 1H), 2.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 140.0, 137.7,
45 131.2, 128.6, 128.5, 128.4, 126.4–126.0 (m, 1C), 119.2–118.6 (m, 1C), 106.5, 21.2; HRMS
46 (ESI-TOF) m/z : (M+H)⁺ Calcd for C₁₂H₁₁D₂N₂ 187.1204; found 187.1200.
47
48
49
50
51

52
53
54 *(Z)*-3-(1*D*-Pyrazol-1-yl)prop-2-en-1-ol (**10c**). The product was obtained as a yellow
55 semi-solid (39.3 mg, 62% yield), ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, 1H), 6.30–6.29 (m,
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1H), 4.49–4.48 (m, 2H), 3.61 (br s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.1–143.7 (m, 1C), 140.5, 126.8–126.7 (m, 1C), 107.0, 99.1–98.9 (m, 1C), 63.3; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_6\text{H}_7\text{D}_2\text{N}_2\text{O}$ 127.0840; found 127.0835.

(Z)-1-(1,2-Di-*p*-tolylvinyl)-1*D*-pyrazole (**10d**). The product was obtained as a pale white semi-solid (82.8 mg, 60% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.76 (s, 1H), 7.37 (s, 1H), 7.15–7.08 (m, 4H), 7.00 (d, $J = 8.3$ Hz, 2H), 6.67 (d, $J = 8.3$ Hz, 2H), 2.34 (s, 3H), 2.28 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.7, 138.7, 137.9, 137.3, 135.0, 131.4, 129.4, 129.2, 128.7, 126.0, 125.8, 124.1–123.3 (m, 1C), 106.9–106.4 (m, 1C), 21.3, 21.2; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{19}\text{H}_{18}\text{DN}_2$ 276.1611; found 276.1612.

(Z)-1-Styryl-1*H*-pyrazole (**10e**). The product was obtained as a orange semi-solid (56.2 mg, 65% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.608–7.601 (m, 1H), 7.37–7.35 (m, 2H), 7.30–7.26 (m, 2H), 7.21–7.17 (m, 1H), 6.339–6.332 (m, 0.85H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0–140.8 (m, 1C), 134.8, 128.7, 128.5–128.4 (m, 1C), 127.4, 127.1–127.0 (m, 1C), 126.0, 116.6–116.4 (m, 1C), 107.0–106.9 (m, 1C); HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{11}\text{H}_8\text{D}_3\text{N}_2$ 174.1111; found 174.1110.

(Z)-1-Styryl-1*H*-pyrazole (**10h**). The product was obtained as a brown semi-solid (48.1 mg, 55% yield), ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, $J = 7.7$ Hz, 2H), 7.48–7.44 (m, 2H), 7.38–7.35 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.1–141.0 (m, 1C), 135.0, 128.8, 127.9–127.8 (m, 1C), 127.5, 126.4–126.3 (m, 1C), 126.1, 116.9–116.6 (m, 1C), 107.3–107.1 (m, 1C), 106.3; HRMS (ESI-TOF) m/z : $(\text{M}+\text{H})^+$ Calcd for $\text{C}_{11}\text{H}_6\text{D}_5\text{N}_2$ 176.1236; found 176.1217.

1-Phenethyl-1*H*-pyrazole (**11a**). The product was obtained as a light brown semi-solid (55.9 mg, 65%); ^1H NMR (400 MHz, CDCl_3) δ 7.526–7.522 (m, 1H), 7.27–7.19 (m, 3H), 7.13 (d, $J = 2.2$

1
2
3 Hz, 1H), 7.06 (d, $J = 6.8$ Hz, 2H), 6.15 (t, $J = 2.2$ Hz, 1H), 4.32 (t, $J = 7.6$ Hz, 2H), 3.14 (t, $J =$
4
5 6.8 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 139.2, 138.0, 129.2, 128.6, 128.4, 126.5, 104.9,
6
7 55.4, 36.8; HRMS (ESI-TOF) m/z : (M+H) $^+$ Calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2$ 173.1079; found 173.1077.
8
9

10
11 *(Z)*-5-Bromo-1-(4-(*p*-tolylethynyl)styryl)-1*H*-indazole (**11b**). The product was obtained as a
12 brown solid (144.2 mg, 70%), mp: 84-86 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.02 (s, 1H), 7.61
13 (d, $J = 8.2$ Hz, 1H), 7.41 (t, $J = 8.7$ Hz, 1H), 7.36–7.30 (m, 3H), 7.28–7.24 (m, 2H), 7.09 (d, $J =$
14 (d, $J = 8.2$ Hz, 1H), 7.41 (t, $J = 8.7$ Hz, 1H), 7.36–7.30 (m, 3H), 7.28–7.24 (m, 2H), 7.09 (d, $J =$
15 7.7 Hz, 2H), 7.02–6.98 (m, 2H), 6.28 (d, $J = 9.1$ Hz, 1H), 2.31 (s, 3H); ^{13}C NMR (100 MHz,
16 CDCl_3): δ 138.9, 138.7, 135.7, 133.3, 131.9, 131.5, 131.3, 130.7, 129.22, 129.16, 127.5, 125.3,
17 123.7, 123.4, 122.3, 121.8, 121.9, 119.8, 113.3, 90.4, 88.8, 21.5; HRMS (ESI-TOF) m/z : (M+H) $^+$
18 Calcd for $\text{C}_{24}\text{H}_{18}\text{BrN}_2$ 413.0653; found 413.0674.
19
20
21
22
23
24
25
26
27

28
29 **Acknowledgement:** The Research work was supported by Council of Scientific and Industrial
30 Research (CSIR) and University of Delhi. V.G and P.B are thankful to CSIR and UGC for
31 fellowship, respectively.
32
33
34
35

36
37 **Supporting Information Available:** Copies of ^1H and ^{13}C NMR and HRMS spectra for
38 compounds are reported. This material is available free of charge via the Internet at
39 <http://pubs.acs.org>.
40
41
42
43

44 References

- 45
46
47 1. Recent Reviews: (a) Taylor, A. P.; Robinson, R. P.; Fobian, Y. M.; Blakemore, D. C.;
48 Jones, L. H.; Fadeyi, O. *Org. Biomol. Chem.* **2016**, *14*, 6611. (b) Ponra, S.; Majumdar, K.
49 C. *RSC Adv.* **2016**, *6*, 37784. (c) Sadjadi, S.; Heravi, M. M.; Nazari, N. *RSC Adv.* **2016**, *6*,
50 53203. (d) Chen, Z. P.; Zhou, Y. G. *Synthesis* **2016**, *48*, 1769. (e) Rohokale, R. S.;
51 Kshirsagar, U. A. *Synthesis* **2016**, *48*, 1253. (f) Ye, Z. S.; Gettys, K. E.; Dai, M. J.
52
53
54
55
56
57
58
59
60

- 1
2
3 Beilstein. *J. Org. Chem.* **2016**, *12*, 702. (g) Kumari, S.; Kishore, D.; Paliwal, S.;
4
5 Chauhan, R.; Dwivedi, J.; Mishra, A. *Mol. Diversity* **2016**, *20*, 185. (h) Khan, I.; Ibrar,
6
7 A.; Abbas, N.; Saeed, A. *Res. Chem. Intermed.* **2016**, *42*, 5147. (i) He, Q.; Yin, Z. Q.;
8
9 Chen, H. B.; Zhang, Z. M.; Wang, X. X.; Yue, G. Z. *Prog. Chem.* **2016**, *28*, 801.
10
11
12
13 2. (a) Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.;
14
15 Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.
16
17 *Pharmacol Rev* **2002**, *54*, 161. (b) Haydl, A. M.; Xu, K.; Breit, B. *Angew. Chem.* **2015**,
18
19 *127*, 7255. (c) Bruno, O.; Brullo, C.; Bondavalli, F.; Schenone, S.; Ranise, A.; Arduino,
20
21 N.; Bertolotto, M. B.; Montecucco, F.; Ottonello, L.; Dallegri, F.; Tognolini, M.;
22
23 Ballabeni, V.; Bertoni, S.; Barocelli, E. *J. Med. Chem.* **2007**, *50*, 3618.
24
25
26
27 3. Selvam, T. P.; Kumar, P. V.; Saravanan, G.; Prakash, C. R. *Journal of Saudi Chemical*
28
29 *Society* **2014**, *18*, 1015.
30
31
32 4. Çetin, A. *Int. J. Curr. Res. Chem. Pharma. Sci.* **2015**, *7*, 8.
33
34 5. Alegaon, S. G.; Alagawadi, K. R.; Dadwe, D. H. *Drug Res.* **2014**, *64*, 553.
35
36 6. Koca, I.; Ozgur, A.; Coskun, K. A.; Tutar, Y. *Bioorg. Med. Chem.* **2013**, *21*, 3859.
37
38 7. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Terauchi, H.; Kawasaki, M.; Wachi, M.;
39
40 Yamagishi, J. I. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4299.
41
42
43 8. Tyagarajan, S.; Chakravarty, P. K.; Zhou, B.; Taylor, B.; Eid, R.; Fisher, M. H.; Parsons,
44
45 W. H.; Wyvratt, M. J.; Lyons, K. A.; Klatt, T.; Li, X.; Kumar, S.; Williams, B.; Felix, J.;
46
47 Priest, B. T.; Brochu, R. M.; Warren, V.; Smith, M.; Garcia, M.; Kaczorowski, G. J.
48
49 *Bioorg. Med. Chem. Lett.* **2010**, *20*, 7479.
50
51
52 9. Shih, S. R.; Chu, T. Y.; Reddy, G.; Tseng, S. N.; Chen, H. L.; Tang, W. F.; Wu, M. S.;
53
54 Yeh, J. Y.; Chao, Y. S.; Hsu, J.; Hsieh, H. P.; Horng, J. T. *J. Biomed. Sci.* **2010**, *17*, 13.
55
56
57
58
59
60

- 1
2
3
4 10. Bandgar, B. P.; Gawande, S. S.; Bodade, R. G.; Gawande, N. M.; Khobragade, C. N.
5
6 *Bioorg. Med. Chem.* **2009**, *17*, 8168.
7
- 8 11. Bole, S. B.; Nargund, R.; Nargund, L. V. G.; Devaraju, K. S.; Vedamurthy, A. B.;
9
10 Shruti, S. D.; *Der Pharma Chemica*, **2011**, *3* (5) 73.
11
- 12 12. Kelekci, G. N.; Koyunoglu, S.; Yabanoglu, S.; Yelekci, K.; Ozgen, O.; Ucar, G.; Erol,
13
14 K.; Kendi, E.; Yesilada, A. *Bioorg. Med. Chem.* **2009**, *17*, 675.
15
- 16 13. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.;
17
18 Makriyannis, A. *J. Med. Chem.* **1999**, *42*, 769.
19
- 20 14. Damljanovic, I.; Evic, M. V.; Radulovic, N.; Palic, R.; Ellmerer, E.; Ratkovic, Z. *Bioorg.*
21
22 *Med. Chem. Lett.* **2009**, *19*, 1093.
23
- 24 15. (a) Alegaon, S. G.; Hirpara, M. B.; Alagawadi, K. R.; Hullatti, K. K.; Kashniyal, K. *Bioorg.*
25
26 *Med. Chem. Lett.* **2014**, *24*, 5324. (b) Li, X.; He, Li.; Chen, H.; Wu, W.; Jiang, H. *J. Org.*
27
28 *Chem.* **2013**, *78*, 3636. (c) Tang, X.; Huang, L.; Yang, J.; Xu, Y.; Wu, W.; Jiang, H.
29
30 *Chem. Commun.*, **2014**, *50*, 14793.
31
- 32 16. Fustero, S.; Rosell, M. S.; Barrio, P.; Sim, A. *Chem. Rev.* **2011**, *111*, 6984.
33
34
- 35 17. (a) Mano, N.; Kim, H. H.; Zhang, Y.; Heller, A. *J. Am. Chem. Soc.* **2002**, *124*, 6480. (b)
36
37 Aggarwal, V. K.; Vicente, J. De.; Bonnert, R. V. *J. Org. Chem.* **2003**, *68*, 5381. (c)
38
39 Taillefer, M.; Ouali, A.; Renard, B.; Spindler, J. F. *Chem. Eur. J.* **2006**, *12*, 5301. (d)
40
41 Kaddouri, H.; Vicente, V.; Ouali, A.; Ouazzani, F.; Taillefer, M. *Angew. Chem. Int. Ed.*
42
43 **2009**, *48*, 333.
44
- 45 18. (a) Rodriguez, A.; Koradin, C.; Dohle, W.; Knochel, P. *Angew. Chem., Int. Ed.* **2000**, *39*,
46
47 2488. (b) Koradin, C.; Dohle, W.; Rodriguez, A.; Schmid, B.; Knochel, P. *Tetrahedron*
48
49 **2003**, *59*, 1571.
50

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Johnson, J. S.; Bergman, R. G. *J. Am. Chem. Soc.* **2001**, *123*, 2923
20. (a) Heutling, A.; Doye, S. *J. Org. Chem.* **2002**, *67*, 1961. (b) Bytschkov, I.; Doye, S. *Eur. J. Org. Chem.* **2003**, 935.
21. Seayad, J.; Tillack, A.; Hartung, C. G.; Beller, M. *Adv. Synth. Catal.* **2002**, *344*, 795.
22. Lutete, L. M.; Kadota, I.; Yamamoto, Y. *J. Am. Chem. Soc.* **2004**, *126*, 1622.
23. Imahori, T.; Hori, C.; Knodo, Y. *Adv. Synth. Catal.* **2004**, *346*, 1090.
24. (a) Ackermann, L. *Org. Lett.* **2005**, *7*, 439. (b) Ackermann, L.; Song, W.; Sandmann, R. *J. Organomet. Chem.* **2011**, *696*, 195.
25. (a) Sun, J.; Kozmin, S. A. *Angew. Chem., Int. Ed.* **2006**, *45*, 4991. (b) Y. Zhang, J. P. Donahue, Li, C. *J. Org. Lett.* **2007**, *9*, 627. (c) Alsabeh, P.G.; R. Lundgren, J.; Longobardi, L. E.; Stradiotto, M. *Chem. Commun.* **2011**, *47*, 6936.
26. (a) Dehli, J. R.; Legros, J.; Bolm, C. *Chem. Commun.* **2005**, 973. (b) Kantam, M. L.; Venkanna, G. T.; Kumar, K. B. S.; Subrahmanyam, V. B. *Chimica Acta* . **2010**, *93*, 974.
27. Tsuchimoto, T.; Aoki, K.; Wagatsuma, T.; Suzuki, Y. *Eur. J. Org. Chem.* **2008**, 4035.
28. (a) Das, U. K.; Bhattacharjee, M. *J. Organomet. Chem.* **2012**, *700*, 78. (b) Das, U. K.; Mandal, S.; Anoop, A.; Bhattacharjee, M. *J. Org. Chem.* **2014**, *79*, 9979.
29. Dvorko, M. Y.; Schmidt, E. Y.; Glotova, T. E.; Shabalin, D. A.; Ushakov, I. A.; Kobychhev, V. B.; Petrushenko, K. B.; Mikhaleva, A. I.; Trofimov, B. A. *Tetrahedron* **2012**, *68*, 1963.
30. (a) Verma, A. K.; Kesharwani, T.; Singh, J.; Tandon, V.; Larock, R. C. *Angew. Chem. Int. Ed.* **2009**, *48*, 1138. (b) Verma, A. K.; Joshi, M.; Singh, V. P. *Org. Lett.* **2011**, *13*, 1630. (c) Joshi, M.; Patel, M.; Tiwari, R. K.; Verma, A. K. *J. Org. Chem.* **2012**, *77*, 5633. (d) Verma, A. K.; Jha, R. R.; Chaudhary, R.; Tiwari, R. K.; Reddy, K. S. K.; Danodia, A. J.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Org. Chem.* **2012**, *77*, 8191. (e) Joshi, M.; Tiwari, R.; Verma, A. K. *Org. Lett.* **2012**, *14*, 1106. (f) Verma, A. K.; Patel, M.; Joshi, M.; Likhar, P. R.; Tiwari, R. K.; Parang, K. *J. Org. Chem.* **2014**, *79*, 172. (g) Patel, M.; Saunthawal, R. K.; Verma, A. K. *Tetrahedron Lett.* **2014**, *55*, 1310. (h) Patel, M.; Saunthawal, R. K.; Verma, A. K. *Acc. Chem. Res.* **2017**, *50*, 240.
31. (a) Patel, M.; Saunthawal, R. K.; Dhaked, D. K.; Bharatam, P. V.; Verma, A. K. *Asian J. Org. Chem.*, **2015**, *4*, 894. (b) Patel, M.; Saunthawal, R. K.; Dhaked, D. K.; Bharatam, P. V.; Verma, A. K. *Asian J. Org. Chem.*, **2016**, *5*, 213.
32. (a) Nimesh, H.; Sur, S.; Sinha, D.; Yadav, P.; Anand, P.; Bajaj, P.; Viridi, J. S.; Tandon, V. *J. Med. Chem.* **2014**, *57*, 5238. (b) Liang, Y.; Xie, Y. X.; Li, J. H. *J. Org. Chem.* **2006**, *71*, 379.